Data as of Nov 26
| +0.06 / +0.38%|
The 11 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 24.00, with a high estimate of 32.00 and a low estimate of 12.00. The median estimate represents a +51.04% increase from the last price of 15.89.
The current consensus among 11 polled investment analysts is to Buy stock in Keryx Biopharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.